OverviewSuggest Edit

Luminex Corporation is a biotechnology company that develops, manufactures, and sells proprietary biological testing technologies and products. Its offerings include flow cytometers, cellular analysis instruments, a platform for genes and proteins measuring, and other diagnostics systems and research tools. It also delivers laboratory software suites and data management software solutions. In addition, the company provides reagents, assays, and test cartridges for various purposes. Luminex caters to markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, and food safety.

HQAustin, TX, US
Employee Ratings3.9
Overall CultureC-

Latest Updates

Employees (est.) (Dec 2020)1,325(+7%)
Job Openings32
Revenue (FY, 2020)$417.4 M(+25%)
Share Price (Jul 2021)$37
Cybersecurity ratingCMore

Key People/Management at Luminex

Nachum Shamir

Nachum Shamir

Chairman, President and Chief Executive Officer
Eric S. Shapiro

Eric S. Shapiro

Senior Vice President, Global Marketing
Harriss T. Currie

Harriss T. Currie

Chief Financial Officer, Senior Vice President, Finance and Treasurer
Todd C. Bennett

Todd C. Bennett

Senior Vice President, Global Sales and Customer Operations
Charles J. Collins

Charles J. Collins

Senior Vice President, Research and Development
Steven Back

Steven Back

Vice President, Global Quality Assurance, Regulatory & Management Representative
Show more

Luminex Office Locations

Luminex has offices in Austin, Madison, Northbrook, Seattle and in 5 other locations
Austin, TX, US (HQ)
12212 Technology Blvd #130
Madison, WI, US
1224 Deming Way
Northbrook, IL, US
4088 Commercial Ave
Seattle, WA, US
645 Elliott Ave W
Toronto, CA
439 University Ave Suite 900
Shanghai, CN
14/F C&D, Building 7, Pujiang Hi-Tech Park 2388 Chenhang Road, Minhang District
Show all (9)

Luminex Financials and Metrics

Luminex Revenue

Embed Graph
View revenue for all periods
Luminex's revenue was reported to be $417.4 m in FY, 2020 which is a 24.7% increase from the previous period.

Revenue (Q1, 2021)


Gross profit (Q1, 2021)


Gross profit margin (Q1, 2021), %


Net income (Q1, 2021)


EBIT (Q1, 2021)


Market capitalization (21-Jul-2021)


Closing stock price (21-Jul-2021)


Cash (31-Mar-2021)



Luminex's current market capitalization is $1.7 b.
USDFY, 2018FY, 2019FY, 2020



Revenue growth, %


Cost of goods sold


Gross profit

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021



Cost of goods sold


Gross profit


Gross profit Margin, %

USDFY, 2018FY, 2019FY, 2020



Accounts Receivable




Current Assets

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021



Accounts Receivable




Current Assets

USDFY, 2018FY, 2019FY, 2020

Net Income


Depreciation and Amortization




Accounts Payable

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income


Depreciation and Amortization




Accounts Payable

USDFY, 2018



Financial Leverage

1.1 x

P/E Ratio

Show all financial metrics

Luminex Acquisitions / Subsidiaries

Company NameDateDeal Size
EMD Millipore Corporation - Flow Cytometry PortfolioDecember 31, 2018$67.98 m
NanosphereJune 30, 2016$68.1 m
GenturaDxJuly 13, 2012$50 m
EraGen BiosciencesJune 27, 2011$34 m
TM BioscienceMarch 02, 2007
Amnis, LLC
ChandlerTec, LLC
Iris Biotech, LLC
Labpac Pty Ltd
Luminex 2 B.V.
Show more

Luminex Revenue Breakdown

Embed Graph

Luminex revenue breakdown by business segment: 11.7% from Consumable Sales, 11.7% from Royalty Revenue, 17.0% from System Sales, 5.6% from Service Revenue, 50.8% from Assay Revenue and 3.3% from Other

Luminex revenue breakdown by geographic segment: 7.2% from Asia, 78.1% from Domestic, 11.7% from Europe and 3.1% from Other

Human Capital Metrics

Source: www.sec.gov
Embed Graph
Show all human capital metrics

Luminex Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Luminex Online and Social Media Presence

Embed Graph

Luminex Company Culture

  • Overall Culture



  • CEO Rating



  • Compensation



Learn more on Comparably

Luminex News and Updates

Luminex Corporation (LMNX) Ex-Dividend Date Scheduled for June 16, 2021

Luminex Corporation (LMNX) will begin trading ex-dividend on June 16, 2021. A cash dividend payment of $0.1 per share is scheduled to be paid on July 08, 2021. Shareholders who purchased LMNX prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 3rd quarter that LM…

Luminex Corp (LMNX) gains 0.2170% for June 10

Luminex Corp (NASDAQ: LMNX) shares gained 0.2170% to end trading Thursday at $36.90 per share - a net change of $0.08. Shares traded between $36.92 and $36.82 throughout the day.

Luminex Corporation Declares Second Quarter Cash Dividend

Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the second quarter of 2021 of $0.10 per share of common stock payable on July 8, 2021 to stockholders of record as of the close of business June 17, 2021.

DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion

DiaSorin S.p.A. ("DiaSorin"; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation ("Luminex";NASDAQ: LMNX) for a price of USD 37.00 per share in an all-cash transaction. This correspon…

Luminex Submits Joint SARS-CoV-2 and Flu/RSV Respiratory Panel to FDA for Emergency Use Authorization

Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an Emergency Use Authorization application to the U.S. Food and Drug Administration for the company's new multi-analyte respiratory panel combining Flu A/B and respiratory syncytial virus (RSV) targets with the SARS-CoV-2 targe…

Luminex Receives FDA Emergency Use Authorization and CE Mark for Expanded NxTAG® Respiratory Panel Test Including SARS-CoV-2

Luminex Corporation (NASDAQ: LMNX) today announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a new expanded version of its NxTAG® Respiratory Pathogen Panel (RPP) that includes the SARS-CoV-2 virus for high-throughput respiratory test…
Show more

Luminex Blogs

Extracellular Vesicles Reimagined with Multiplex Color Detection in Imaging Flow Cytometry

Extracellular vesicles (EVs) have caught scientists’ attention in recent years. These sub-micron particles are part of a vast cell-to-cell communication network within the body, delivering important biochemical signals from one cell to others. [Read More...] The post Extracellular Vesicles Reimagin…

5 Ways the New xMAP® INTELLIFLEX System Will Empower Your Research

With several new features, INTELLIFLEX offers far more than just five benefits for researchers looking to expand their discovery, but we know that in this day and age, your time is more precious than ever, so we’ve consolidated the key benefits here to provide a summary of the top five ways xMAP INT…

The Faces of Luminex: Caleb White, Sales

Molecular diagnostics labs have specific needs, and our Molecular Diagnostics Sales Team members are experts in understanding how our products fit into unique workflows and testing environments. Caleb White, Molecular Sales Effectiveness Manager, ensures that our newest Sales Team members get up to …

Pre-Operative COVID-19 Testing and the Case for Standalone vs. Paneled SARS-CoV-2 Assays

Because hospitals and healthcare facilities continue to see patients for regular treatments, procedures, and surgeries, patient care has evolved to accommodate new standards and safety procedures to help slow the spread of COVID-19 and protect both patients and healthcare workers. [Read More...] Th…

The Faces of Luminex: Wilco de Jager, LTG Field Applications

When our commercial partners need help building or refining their assays, Wilco draws on his extensive xMAP Technology knowledge to bring those assays to life. [Read More...] The post The Faces of Luminex: Wilco de Jager, LTG Field Applications appeared first on Luminex Corporation.

Why Researchers Love xMAP® Technology

Since the breakthrough that led to the development of xMAP® Technology—the original idea that using different fluorophore colors could enable the detection of more than one analyte at a time—we have continued to build on what xMAP Technology can do, working with researchers from around the world to …
Show more

Luminex Frequently Asked Questions

  • When was Luminex founded?

    Luminex was founded in 1995.

  • Who are Luminex key executives?

    Luminex's key executives are Nachum Shamir, Eric S. Shapiro and Harriss T. Currie.

  • How many employees does Luminex have?

    Luminex has 1,325 employees.

  • What is Luminex revenue?

    Latest Luminex annual revenue is $417.4 m.

  • What is Luminex revenue per employee?

    Latest Luminex revenue per employee is $315 k.

  • Who are Luminex competitors?

    Competitors of Luminex include Cepheid, Repligen and Olink.

  • Where is Luminex headquarters?

    Luminex headquarters is located at 12212 Technology Blvd #130, Austin.

  • Where are Luminex offices?

    Luminex has offices in Austin, Madison, Northbrook, Seattle and in 5 other locations.

  • How many offices does Luminex have?

    Luminex has 9 offices.